Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1997 1
1998 2
2000 1
2001 1
2002 1
2003 1
2005 1
2006 1
2009 1
2010 4
2011 2
2012 4
2013 3
2014 3
2015 3
2016 6
2017 7
2018 5
2019 2
2020 6
2021 6
2022 7
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M. Danne T, et al. Among authors: ampudia blasco fj. Diabetes Care. 2019 Jun;42(6):1147-1154. doi: 10.2337/dc18-2316. Epub 2019 Feb 6. Diabetes Care. 2019. PMID: 30728224 Free PMC article. Review.
Time-in-range for monitoring glucose control: Is it time for a change?
Bellido V, Pinés-Corrales PJ, Villar-Taibo R, Ampudia-Blasco FJ. Bellido V, et al. Among authors: ampudia blasco fj. Diabetes Res Clin Pract. 2021 Jul;177:108917. doi: 10.1016/j.diabres.2021.108917. Epub 2021 Jun 11. Diabetes Res Clin Pract. 2021. PMID: 34126129 Review.
Biosimilars and Novel Insulins.
Ampudia-Blasco FJ. Ampudia-Blasco FJ. Am J Ther. 2020 Jan/Feb;27(1):e52-e61. doi: 10.1097/MJT.0000000000001079. Am J Ther. 2020. PMID: 31764128
Current barriers to initiating insulin therapy in individuals with type 2 diabetes.
Galdón Sanz-Pastor A, Justel Enríquez A, Sánchez Bao A, Ampudia-Blasco FJ. Galdón Sanz-Pastor A, et al. Among authors: ampudia blasco fj. Front Endocrinol (Lausanne). 2024 Mar 14;15:1366368. doi: 10.3389/fendo.2024.1366368. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38559691 Free PMC article. Review.
Diabetes and the WHO Model List of Essential Medicines.
Danne T, Ampudia-Blasco FJ, Mathieu C. Danne T, et al. Among authors: ampudia blasco fj. Lancet Diabetes Endocrinol. 2022 Jan;10(1):18-19. doi: 10.1016/S2213-8587(21)00322-3. Lancet Diabetes Endocrinol. 2022. PMID: 34919865 No abstract available.
Expert Recommendations for Using Time-in-Range and Other Continuous Glucose Monitoring Metrics to Achieve Patient-Centered Glycemic Control in People With Diabetes.
Bellido V, Aguilera E, Cardona-Hernandez R, Diaz-Soto G, González Pérez de Villar N, Picón-César MJ, Ampudia-Blasco FJ. Bellido V, et al. Among authors: ampudia blasco fj. J Diabetes Sci Technol. 2023 Sep;17(5):1326-1336. doi: 10.1177/19322968221088601. Epub 2022 Apr 26. J Diabetes Sci Technol. 2023. PMID: 35470692 Free PMC article. Review.
[Future of glitazones].
Ampudia-Blasco FJ. Ampudia-Blasco FJ. Med Clin (Barc). 2011 Jun 11;137(1):20-1. doi: 10.1016/j.medcli.2011.02.001. Epub 2011 Mar 27. Med Clin (Barc). 2011. PMID: 21444097 Spanish. No abstract available.
70 results